Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $759000.0.

  • Ernexa Therapeutics' Non Operating Income rose 10311.92% to $759000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 6777.53%. This contributed to the annual value of -$28.8 million for FY2024, which is 527966.42% down from last year.
  • Per Ernexa Therapeutics' latest filing, its Non Operating Income stood at $759000.0 for Q3 2025, which was up 10311.92% from -$635000.0 recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Non Operating Income high stood at $10.5 million for Q2 2022, and its period low was -$24.3 million during Q3 2024.
  • Moreover, its 5-year median value for Non Operating Income was -$280000.0 (2023), whereas its average is -$2.1 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Non Operating Income surged by 45365.85% in 2021, and later crashed by 2578617.02% in 2024.
  • Over the past 5 years, Ernexa Therapeutics' Non Operating Income (Quarter) stood at $290000.0 in 2021, then fell by 0.69% to $288000.0 in 2022, then plummeted by 188.54% to -$255000.0 in 2023, then crashed by 1096.47% to -$3.1 million in 2024, then surged by 124.88% to $759000.0 in 2025.
  • Its last three reported values are $759000.0 in Q3 2025, -$635000.0 for Q2 2025, and -$5.5 million during Q1 2025.